We are international

Call the IMF Hotline. We are here for you. The IMF Office is open from 8:00AM - 5:00PM PST, Monday-Friday.

If you have a question, call the IMF InfoLine at (800) 452-CURE (800-452-2873) in the US and Canada. The InfoLine is open from 9:00 - 4:00 PT Monday - Friday. Elsewhere call (818) 487-7455. You can also contact us via the web.
IMF - Home Page
previous     next      view all

The International Myeloma Foundation (IMF) Announces Publication of New Diagnostic Guidelines to Better Assess Patients and Guide Treatment

Revisions to the International Staging System by the IMF’s International Myeloma Working Group Reported in the Journal of Clinical Oncology

Click here to watch the "Advocacy in August: How to Connect with your Representative at Home" replay
With the Congressional August recess in full swing, this webinar will give you the tools to educate your members of Congress on the issues that matter most to you and the multiple myeloma community. Whether you’re new to advocacy or a veteran, this webinar is not to be missed! The presentation will focus on breaking down the advocacy process, helping you understand the issues, and teaching you how to get the most out of the resources available to you. To watch the replay, please click HERE.

Is There a Link Between a Genetic Variation and Poor Myeloma Survival Rate?
In his blog this week, IMF Chairman Dr. Brian Durie comments on news about a multi-institutional study that found patients with multiple myeloma with a genetic variation in the gene FOPNL have poorer outcomes than patients without it. “As one might suspect, much further work is needed to substantiate and understand this finding,” he notes, “but this initial report is quite tantalizing.” To read Dr. Durie’s blog, click HERE

European Medicines Agency Grants Accelerated Assessment of Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted an accelerated assessment to ixazomib, an investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma.

FDA Approves Kyprolis® (Carfilzomib) for Combination Use in the Treatment of Patients with Relapsed Multiple Myeloma

Approval Expands Kyprolis Indication. Patients Treated With Kyprolis in Combination With Standard of Care Lived 50 Percent Longer Without Disease Worsening Compared to Standard of Care Alone in Pivotal Study

IMF's Black Swan Research Initiative Makes Inroads on Pathway to a Cure
The Black Swan Research Initiative® is moving ahead on all fronts, reports IMF Chairman Dr. Brian Durie in his blog this week. “The stage is set to include standardized MRD testing into clinical trials. And we continue to work on additional and simpler testing, such as a new blood test for early diagnosis and monitoring.” Also this week, a follow-up on possible connections between sitting too much and myeloma—but not what you’d expect! To read Dr. Durie’s blog, click HERE.

Members of International Myeloma Foundation’s Nurse Leadership Board Author Key Textbook for Nurses

Book Updates the First Comprehensive Review by and For Nurses 

Calling All Researchers: Submit Your Applications for 2016 IMF Grants
The IMF awards Brian D. Novis Junior and Senior Research Grants each year to "provide much-needed funding support for research projects being conducted by the best and the brightest in our field," according to IMF President Susie Novis. Funding grants since 1994 to honor IMF Co-Founder Brian D. Novis, the IMF has awarded more than 140 grants in 13 countries, which have opened the doors to new ideas and major advancements in treatments. Applications for 2016 grants are due by August 3rd. To submit an application, click HERE.

Expanded Access Program Opens for Daratumumab
Janssen Biotech, Inc. has announced the opening of a daratumumab expanded access program (EAP) at up to 40 medical centers for eligible US myeloma patients who have received at least 3 prior lines of therapy (including a proteasome inhibitor and an immunomodulatory agent) or are double refractory to a proteasome inhibitor and an immunomodulatory agent. Daratumumab is currently an investigational human anti-CD38 monoclonal antibody treatment for multiple myeloma. To learn more about the EAP for daratumumab, contact the IMF InfoLine at (800) 452-2873 or email infoline@myeloma.org.

New Drug Application Filed with FDA for Oral Proteasome Inhibitor
Takeda has filed for FDA approval of ixazomib, which could become the first oral proteasome inhibitor for treating multiple myeloma. The New Drug Application (NDA) for ixazomib is based on the results of the phase III TOURMALINE-MM1 trial, which compared ixazomib to placebo—both given in 772 patients with relapsed or refractory myeloma. “If approved, ixazomib, with the convenience of once-a-week oral administration as well as promising efficacy, should provide a very meaningful advance for our patients,” said Dr. Paul Richardson, Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center Institute Physician at Dana-Farber Cancer Institute. Click HERE to read the announcement.

previous     next      view all